Cidara Therapeutics (CDTX) Reports Q4 Loss of $0.88/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
March 15, 2017 5:22 PM EDTSAN DIEGO, March 15, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2016 and provided an update on its corporate activities and product pipeline.
Cidara continued to make progress throughout the year in moving our development programs forward, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. We executed on our CD101 clinical programs, strengthened our finances and selected a development candidate, CD201, from our Cloudbreak immunotherapy program for the treatment of multi-drug resistant... More
